Zacks5d agobearish
XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives SalesDENTSPLY SIRONA's Q2 sales fall 4.1% as dental weakness offsets Wellspect growth, while margins improve and 2026 guidance is maintained.
Actualités
Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
327last 24h
2137last 7d
376● bullish (7d)
188● bearish (7d)
204publishers
Zacks6d agobearish
PacBio Q2 Earnings Meet Estimates, Revenues Miss, 2026 Sales View CutPACB cuts its 2026 revenue outlook after Q2 sales fall 2%, as consumables and EMEA growth fail to offset weaker instruments and Asia-Pacific.
Zacks7d agobearish
FMS Q2 Earnings Rise on Care Delivery, Revenues Miss, Margins ExpandFMS posts 28% EPS growth as Care Delivery profitability and margin gains offset a quarterly revenue miss and weaker US treatment volumes.
Zacks12d agobearish
SYK Falls Despite Q2 Earnings Beat on Strong Sales and Cyber RecoveryStryker tops Q2 estimates as sales regain momentum after a cyber disruption, but narrowed 2026 guidance weighs on shares, sending them down 7.8% in after-hours trading.
Zacks26d agobearish
ISRG Q2 Earnings Beat Estimates, Stock Falls on Slow Procedure GrowthISRG beats second-quarter earnings and revenue estimates, but shares fall after hours as procedure growth slows sequentially despite strong placements.
Simply Wall St.33d agobearish
West Pharmaceutical Services (WST) Sells SmartDose Rights To AbbVie To Refocus Its BusinessWest Pharmaceutical Services (NYSE:WST) has sold the rights and facilities related to its SmartDose 3.5 mL On Body Delivery System to AbbVie. The transaction shifts ownership of this specific large volume wearable injector platform while allowing West Pharmaceutical Services to focus on other drug delivery offerings. The deal reflects a change in how NYSE:WST is positioning its portfolio within the drug delivery and pharmaceutical packaging market. West Pharmaceutical Services operates in...
Zacks90d agobearish
Doximity Stock Falls on Q4 Earnings Miss, Revenues Beat, Margins DownDOCS' revenues top estimates as AI tool adoption and large customer growth fuel engagement despite weaker earnings and margin pressure.